Biohybrid Expands Technology Base.Business Editors, Health & Medical Writers DENVER--(BW HealthWire)--March 13, 2000 Biohybrid, Inc., Denver, Colorado, announced today that it has purchased the patent rights to CD8-mediated veto from TKB TKB Terrorism Knowledge Base (National Memorial Institute for the Prevention of Terrorism) TKB Tappa Kegga Brew TKB The-Killer-Brothers (gaming clan) TKB Troubleshooting Knowledge Base TKB Task Builder Associates, Cleveland, Ohio. TKB Associates will receive an equity position in the company as well as royalty and milestone payments. Biohybrid, Inc. is developing immune suppressive sup·pres·sive adj. Tending or serving to suppress. Adj. 1. suppressive - tending to suppress; "the government used suppressive measures to control the protest" compounds that exploit the "veto effect." The company's product platform of hybrid antibodies and genetically engineered genetically engineered adjective Recombinant, see there vectors are agents for the treatment of graft rejection, graft-versus-host disease, and autoimmune disorders. Its products selectively suppress a subset of white blood cells White blood cells A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies that are programmed to destroy the graft. Dr. Paula Konigsberg, Director of Drug Development for the company, stated: "We are very pleased to have completed this. The acquisition of this technology allows us to move forward in our growth." |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion